International Journal of Hematology

, Volume 76, Issue 3, pp 279–283 | Cite as

Treatment with Cerivastatin in Primary Mixed Hyperlipidemia Induces Changes in Platelet Aggregation and Coagulation System Components

  • A. Ugur Ural
  • M. Ilker Yilmaz
  • Ferit Avcu
  • Atilla Yalcin
Case Report

Abstract

Platelet activation, impairment of fibrinolysis, activation of the coagulation pathway, and dyslipidemia are important factors in the pathogenesis and progression of ischemic heart disease, and patients generally need to use an antiplatelet agent. Lipid-lowering cerivastatin, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, was administered to 20 patients with primary mixed hyperlipidemia for the assessment of the effect of cerivastatin on lipid levels, plasma fibrinogen concentration, factor VII, VIII, and X levels, plasminogen and antiplasmin concentrations, platelet count, and aggregation (adenosine diphosphate [ADP], collagen, and epinephrine induced). Assessments were made immediately after 2 months of a standard lipid-lowering diet, 4 weeks of placebo administration, and 4 weeks of cerivastatin treatment. Cerivastatin achieved significant reductions in triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels. The significant improvement of the lipid profile was associated with platelet aggregation reduction in vitro stimulated by ADP, collagen, and epinephrine (P > .05,P = .05,P > .005, respectively). Significantly lower levels of factor VII and fibrinogen were observed (P = .001,P > .0001) immediately after cerivastatin treatment. No significant differences were detected in factor VIII level, plasminogen and antiplasmin concentrations, and platelet count after cerivastatin treatment. It was concluded that cerivastatin in mixed hyperlipidemia can exert beneficial changes on specific hemostatic variables and platelet aggregation in addition to its positive effects on plasma lipid values.

Key words

Cerivastatin Hyperlipidemia Coagulation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis.N Engl J Med. 1983;309:288–296.CrossRefGoogle Scholar
  2. 2.
    Arad Y, Ramakrishnan E, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing production of apoB-containing lipoproteins: implications for pathophysiology of apoB production.J Lipid Res. 1990;31:567–582.Google Scholar
  3. 3.
    Stephard J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N Engl J Med. 1995;333:1301–1307.CrossRefGoogle Scholar
  4. 4.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994;3441:383–389.Google Scholar
  5. 5.
    Beigel Y, Fuchs J, Snir M, Lurie Y, Green P, Djaldetti M. Lovastatin therapy in heterozygous familial hypercholesterolemic patients: effect on blood rheology and fibrinogen levels.J Intern Med. 1991; 230:23–27.CrossRefGoogle Scholar
  6. 6.
    Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets.Br J Clin Pharmacol. 1997;44:77–83.CrossRefGoogle Scholar
  7. 7.
    Sandset PM, Lund H, Norseth J, Abildguard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.Arterioscler Thromb. 1991;11: 138–145.CrossRefGoogle Scholar
  8. 8.
    Silveria A, Karpe F, Blomback M. Activation of coagulation factor VII during alimentary lipidemia.Arterioscler Thromb. 1994;14: 60–69.CrossRefGoogle Scholar
  9. 9.
    Mitropoulos KA, Miller GJ, Reeves BEA,Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men.Atherosclerosis. 1989;76:203–208.CrossRefGoogle Scholar
  10. 10.
    Farnier M. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT Study. The Cerivastatin Study Group.Am J Cardiol. 1998;82:515–525.CrossRefGoogle Scholar
  11. 11.
    Mabuchi H, Koizumi J, Kajinami K. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholes-terolemia.Am J Cardiol. 1998;82:525–555.CrossRefGoogle Scholar
  12. 12.
    Friedwald WT, Levy RI, Frederikson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preoperative ultracentrifuge.Clin Chem. 1972;18: 499–502.Google Scholar
  13. 13.
    Kisiel W, McMullen BA. Isolation and characterization of human factor VIIa.Thromb Res Suppl. 1981;22:375–380.CrossRefGoogle Scholar
  14. 14.
    Zacharski LR, Rosenstein R. Standardization of the one-stage assay for factor VIII.Am J Clin Pathol. 1978;70:280–286.CrossRefGoogle Scholar
  15. 15.
    Fair DS, Edgington TS. Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.Br J Haematol. 1985;59:235–248.CrossRefGoogle Scholar
  16. 16.
    Koepke JA, Gilmer PR, Jr Filip DJ, et al. Studies of fibrinogen measurement in the CAP survey program.Am J Clin Pathol. 1975; 63:984–989.Google Scholar
  17. 17.
    Wohl RC, Sinio L, Robbins KC. Methods for studying fibrinolytic pathway components in human plasma.Thromb Res Suppl. 1982; 27:525–535.CrossRefGoogle Scholar
  18. 18.
    Reddy KNN, Marcus G. Mechanisms of activation of human plasminogen by streptokinase: presence of active center in streptoki-nase-plasminogen complex.J Biol Chem. 1972;247:1683.Google Scholar
  19. 19.
    Stein E. Cerivastatinin primary hyperlipidemia: a multicenter analysis of efficacy and safety.Am J Cardiol. 1998;82:40J-46J.CrossRefGoogle Scholar
  20. 20.
    Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.Lancet. 1993;324:1076–1079.CrossRefGoogle Scholar
  21. 21.
    Harker LA, Ritchie JL. The role of platelets in acute vascular events.Circulation. 1980;62:V13-V18.Google Scholar
  22. 22.
    Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy.Circulation. 1981;63:546–551.CrossRefGoogle Scholar
  23. 23.
    Shastri KM, Carvlho ACA, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias.J Lipid Res. 1980;21: 467–478.Google Scholar
  24. 24.
    Mort G, Bulgarelli A, Casseder M, Pagaso G. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.Atherosclerosis. 1988;71:113–119.CrossRefGoogle Scholar
  25. 25.
    Nordoy A, Simonsen T, Ytre-Arne K, Lyngmo V, Svensson B. The effect of two cholesterol lowering agents on platelets in patients with hypercholesterolemia.Thromb Haemost. 1987;58:1002.Google Scholar
  26. 26.
    Brook G, Winterstein G, Aviram M. Platelet function and lipoprotein levels after plasma exchange in patients with familial hypercholesterolemia.Clin Sci (Lond). 1983;64:637–642.CrossRefGoogle Scholar
  27. 27.
    Aviram M, Brook JG. Selective release from platelet granules induced by plasma lipoproteins.Biochem Med. 1984;32:30–33.CrossRefGoogle Scholar
  28. 28.
    Aviram M, Brook JG. Platelet interaction with high and low density lipoproteins.Atherosclerosis. 1983;46:259–268.CrossRefGoogle Scholar
  29. 29.
    Nordoy A, Refsum N, Thelle D, Jaeger S. Platelet function and serum high density lipoproteins.Thromb Haemost. 1979;42: 1181–1186.Google Scholar
  30. 30.
    Desai K, Bruckdorfer KR, Hutton RA, Owen JS. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation.J Lipid Res. 1989;30:831–840.Google Scholar
  31. 31.
    Dajani EZ, Shahwan TG, Dajani NE. Statins, platelet aggregation and coronary heart disease.J Assoc Acad Minor Phys. 2002;13: 27–31.Google Scholar
  32. 32.
    Ma LP, Nie DN, Hsu SX, Yin SM, Xu LZ, Nunes JV. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia.J Assoc Acad Minor Phys. 2002;13:23–26.Google Scholar
  33. 33.
    Owen J, Grossman BA, Palmer RH. Hyperlipidemia and in vivo hemostatic system activation.Semin Thromb Hemost. 1988;14: 241–245.CrossRefGoogle Scholar
  34. 34.
    Kannel WB, Wolf P, Castelli WP, D’Agostino R. Fibrinogen and risk of cardiovascular disease: the Framingham Study.JAMA. 1987;258: 1183–1186.CrossRefGoogle Scholar
  35. 35.
    Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hyper cholesterolemia.Thromb Haemost. 1993;70:241–243.Google Scholar
  36. 36.
    Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment.Atherosclerosis. 1990;85:249–256.CrossRefGoogle Scholar
  37. 37.
    Zambrana JL, Velasco F, Castro P, et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipidemic heart transplant patients.Am J Cardiol. 1997;80:836–840.CrossRefGoogle Scholar
  38. 38.
    Meade TW, Mellows S, Brozovic M. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.Lancet. 1986;2:533–537.CrossRefGoogle Scholar
  39. 39.
    Mitropoulos KA, Miller GJ, Martin JC, Reeves BEA, Cooper J. Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration.Arterioscler Thromb. 1994;14:214–222.CrossRefGoogle Scholar
  40. 40.
    Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Oxford Cholesterol Study Group.Eur Heart J. 1997;18:235–241.CrossRefGoogle Scholar
  41. 41.
    Hamsten A, Wiman B, Faire deU, Blomback M.Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.N Engl J Med. 1985;313:1557–1563.CrossRefGoogle Scholar
  42. 42.
    Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator-1 expression by human vascular smooth muscle and endothelial cells.Arterioscler ThrombVasc Biol. 2000;20:556–562.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • A. Ugur Ural
    • 1
    • 2
  • M. Ilker Yilmaz
    • 3
  • Ferit Avcu
    • 1
  • Atilla Yalcin
    • 1
  1. 1.Departments of HematologyGulhane Military Medical Academy, School of MedicineAnkaraTurkey
  2. 2.Departments of Medical Research CenterGulhane Military Medical AcademyAnkaraTurkey
  3. 3.Departments of Internal MedicineGulhane Military Medical AcademyAnkaraTurkey

Personalised recommendations